2010
DOI: 10.1002/cmdc.200900520
|View full text |Cite
|
Sign up to set email alerts
|

Isolation of a Small‐Molecule Inhibitor of the Antiapoptotic Protein Bcl‐xL from a DNA‐Encoded Chemical Library

Abstract: Bcl-xL is an antiapoptotic member of the Bcl-2 protein family and an attractive target for the development of anticancer agents. Here we describe the isolation of binders to Bcl-xL from a DNA-encoded chemical library using affinity-capture selections and massively parallel high-throughput sequencing of >30,000 sequence tags of library members. The most potent binder identified, compound 19/93 [(R)-3-(amido indomethacin)-4-(naphthalen-1-yl)butanoic acid], bound to Bcl-xL with a dissociation constant (K(d)) of 9… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
46
0

Year Published

2011
2011
2016
2016

Publication Types

Select...
5
4

Relationship

2
7

Authors

Journals

citations
Cited by 53 publications
(48 citation statements)
references
References 49 publications
2
46
0
Order By: Relevance
“…Dumelin and D. Neri30. Since then, the protocol was used to screen different DECLs, allowing for the identification of small molecule binders against alpha-1-acid glycoprotein31, B-cell lymphoma-extra large15,64, bovine serum albumin19, carbonic anhydrase II30, carbonic anhydrase IX17,31, human serum albumin15,19,20,22,30, interleukin 216, matrix metalloproteinase 365, prostate-specific membrane antigen20, rabbit serum albumin19, streptavidin66,67, tankyrase 120,21, trypsin15,68,69 and tumor necrosis factor alpha15. Over the past decade, literally all parts of the protocol were improved significantly: sepharose beads were replaced by magnetic beads, automated followed after manual selections and selection analysis evolved from microarray-based decoding to more cost-efficient HTDS approaches.…”
Section: Introductionmentioning
confidence: 99%
“…Dumelin and D. Neri30. Since then, the protocol was used to screen different DECLs, allowing for the identification of small molecule binders against alpha-1-acid glycoprotein31, B-cell lymphoma-extra large15,64, bovine serum albumin19, carbonic anhydrase II30, carbonic anhydrase IX17,31, human serum albumin15,19,20,22,30, interleukin 216, matrix metalloproteinase 365, prostate-specific membrane antigen20, rabbit serum albumin19, streptavidin66,67, tankyrase 120,21, trypsin15,68,69 and tumor necrosis factor alpha15. Over the past decade, literally all parts of the protocol were improved significantly: sepharose beads were replaced by magnetic beads, automated followed after manual selections and selection analysis evolved from microarray-based decoding to more cost-efficient HTDS approaches.…”
Section: Introductionmentioning
confidence: 99%
“…Success stories have even been reported for carefully designed, smaller libraries containing only thousands of compounds. Using such focused libraries, our group has reported the de novo discovery of micromolar binders against Bcl-xL,[19] Interleukin-2 [20] and TNF. [21] In 2015, a two building block library, containing 103200 compounds, allowed the isolation of binders against a number of proteins, including prostate-specific membrane antigen and tankyrase-1.…”
Section: Single Pharmacophore Dna-encoded Chemical Librariesmentioning
confidence: 99%
“…$ If Ki was not available, IC50 is reported instead. 26,27,28,29,30,31,32,33,34 Using automatic pharmacophore generation and further refinements of the hypotheses, a fivefeature pharmacophore can actually be defined using this dataset. The model can be described as a four-branched star.…”
Section: Is a Unique Binding Site Possible? Building Of A Pharmacophomentioning
confidence: 99%